Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro

被引:46
作者
Shiohara, M
Dawson, MI
Hobbs, PD
Sawai, N
Higuchi, T
Koike, K
Komiyama, A
Koeffler, HP
机构
[1] Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Div Hematol Oncol, Los Angeles, CA 90048 USA
[2] Shinshu Univ, Sch Med, Dept Pediat, Matsumoto, Nagano 390, Japan
[3] SRI Int, Retinoid Program, Menlo Park, CA 94025 USA
关键词
D O I
10.1182/blood.V93.6.2057.406k04_2057_2066
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Retinoids such as all-trans-retinoic acid (ATRA) and 9-cis-retinoic acid (9-cis-RA) have an important role in many aspects of proliferation and differentiation of hematopoietic cells. They exert their effects by binding to retinoic acid receptors (RARs) and/or retinoid X receptors (RXRs). We studied the effects of novel retinoids on proliferation and differentiation of HL-60 and NB4 myeloid leukemic cells, as well as acute promyelocytic leukemia (APL) cells from patients. RXR-selective SR11345 (Retinoid C) had little ability to inhibit the clonal growth and to induce the differentiation of either HL-60 or NB4 cells. However, SR11276 (Retinoid E), which activated both the RAR and RXR classes, and SR11278 (Retinoid D), which activated the RAR subtypes alpha, beta, and gamma, could inhibit clonal growth of both cell types, as well as leukemic cells from APL patients. The combination of ATRA and either SR11276 or SR11278 additively inhibited APL cell proliferation. SR11302 (Retinoid A), with reported anti-AP-1 activity and no activation of RARs and RXR and SR11363 (Retinoid B), which selectively activated RAR beta and gamma, were inactive. The clonal proliferation of both HL-60 and NB4 cells that were pulse-exposed to 10(-9) mol/L ATRA, SR11276, SR11278, or SR11345 for 3 days, washed, and plated in methylcellulose culture were inhibited by 0%, 51%, 21%, and 1% for HL-60 cells and 43%, 41%, 35%, and 1% for NB4, respectively, compared with nontreated control cells. When the HL-60 cells were pulse-exposed to 10-9 mol/L of either SR11278 or SR11276, plus 10-9 mol/L ATRA for 3 days, colony numbers were reduced by 46% and 64%, respectively. Induction of leukemic cell differentiation as determined by the nitroblue tetrazolium (NBT) assay showed that the combination of 10(-7) mol/L of either SR11278 or SR11276 with 10(-7) mol/L ATRA had additive effects on HL-60 cells, NB4 cells, and fresh APL cells. Induction of CD11b expression on both HL-60 and NB4 cells occurs during their differentiation. Expression of this antigen was synergistically augmented by the combination of either 10(-7) to 10(-8) mol/L SR11278 or 10(-7) to 10(-9) mol/L SR11276 with 10(-9) mol/L ATRA compared with either analog alone in HL-60 cells. Expression of the novel myeloid specific transcription factor C/EBP epsilon was increased by SR11278 and SR11276 in both the HL-60 and NB4 cell lines. We conclude that retinoids or combination of retinoids with specificities for both RAR and RXR may markedly enhance the ability of ATRA to inhibit clonal growth and induce differentiation of HL-60 and NB4 leukemic cells. This occurs in the absence of continuous contact with retinoids. (C) 1999 by The American Society of Hematology.
引用
收藏
页码:2057 / 2066
页数:10
相关论文
共 51 条
[1]   A novel human CCAAT/enhancer binding protein gene, C/EBP epsilon, is expressed in cells of lymphoid and myeloid lineages and is localized on chromosome 14q11.2 close to the T-cell receptor alpha/delta locus [J].
Antonson, P ;
Stellan, B ;
Yamanaka, R ;
Xanthopoulos, KG .
GENOMICS, 1996, 35 (01) :30-38
[2]   PROPOSED REVISED CRITERIA FOR THE CLASSIFICATION OF ACUTE MYELOID-LEUKEMIA - A REPORT OF THE FRENCH-AMERICAN-BRITISH COOPERATIVE GROUP [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
ANNALS OF INTERNAL MEDICINE, 1985, 103 (04) :620-625
[3]   INDUCTION OF DIFFERENTIATION OF THE HUMAN PROMYELOCYTIC LEUKEMIA-CELL LINE (HL-60) BY RETINOIC ACID [J].
BREITMAN, TR ;
SELONICK, SE ;
COLLINS, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1980, 77 (05) :2936-2940
[4]   REGULATED EXPRESSION OF 3 C/EBP ISOFORMS DURING ADIPOSE CONVERSION OF 3T3-L1 CELLS [J].
CAO, ZD ;
UMEK, RM ;
MCKNIGHT, SL .
GENES & DEVELOPMENT, 1991, 5 (09) :1538-1552
[5]  
CHEN ZX, 1994, CANCER RES, V54, P3494
[6]   Modulation of mRNA expression of a novel human myeloid-selective CCAAT/Enhancer binding protein gene (C/EBP epsilon) [J].
Chih, DY ;
Chumakov, AM ;
Park, DJ ;
Silla, AG ;
Koeffler, HP .
BLOOD, 1997, 90 (08) :2987-2994
[7]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[8]   RETINOIC ACID THERAPY FOR PROMYELOCYTIC LEUKEMIA [J].
CHOMIENNE, C ;
BALLERINI, P ;
BALITRAND, N ;
AMAR, M ;
BERNARD, JF ;
BOIVIN, P ;
DANIEL, MT ;
BERGER, R ;
CASTAIGNE, S ;
DEGOS, L .
LANCET, 1989, 2 (8665) :746-747
[9]   Cloning of the novel human myeloid-cell-specific C/EBP-epsilon transcription factor [J].
Chumakov, AM ;
Grillier, I ;
Chumakova, E ;
Chih, D ;
Slater, J ;
Koeffler, HP .
MOLECULAR AND CELLULAR BIOLOGY, 1997, 17 (03) :1375-1386
[10]   INHIBITION OF TUMORIGENIC POTENTIAL AND PROSTATE-SPECIFIC ANTIGEN EXPRESSION IN LNCAP HUMAN PROSTATE-CANCER CELL-LINE BY 13-CIS-RETINOIC ACID [J].
DAHIYA, R ;
PARK, HD ;
CUSICK, J ;
VESSELLA, RL ;
FOURNIER, G ;
NARAYAN, P .
INTERNATIONAL JOURNAL OF CANCER, 1994, 59 (01) :126-132